Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.